Company Overview and News
Cerner Corporation (CERN - Free Report) is currently plagued with headwinds like downbeat guidance and stiff competition in niche space. Its no wonder that the company is underperforming in the MedTech space at the moment.
MDRX MCK MS.PRE MS.PRF MS.PRG QSII MS.PRA MS.PRI MS.PRK CERN SYK MS ABMD GHDX
McKesson (MCK) reported final year results recently and there was nothing of note on the recent earnings call to suggest altering our bullish stance. We have been long this stock now since mid-2017, but shares have failed to gain much traction. McKesson seems to be caught up in the whole drug issue unfairly, I believe, which is affecting the main 3 distributors. Shares have thus far failed to take out the mid-2016 highs.
International moats retreated in May, underperforming the broad international market. The Morningstar® Global ex-US Moat Focus IndexSM (MGEUMFUN, or "International Moat Index") trailed the MSCI All Country World Index ex-USA in May by roughly 1% (-3.33% vs. -2.31%, respectively). Domestic moat companies, as represented by the Morningstar Wide Moat Focus IndexSM (MWMFTR, or "U.S. Moat Index"), lagged the S&P 500 Index (1.
SMSOF CQP ABC SMSEY LNG MCK 1910 CAH MCHP CVS MORN
Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of th
Kentucky's attorney general on Thursday sued Walgreens Boots Alliance Inc , accusing the company of playing a dual role in propagating an opioid epidemic in the state as both a pharmacy chain and wholesale drug distributor.
ABC MCK WBA CAH ENL ENDP
June 14 (Reuters) - Kentucky’s attorney general on Thursday sued Walgreens Boots Alliance Inc, accusing the company of playing a dual role in propagating an opioid epidemic in the state as both a pharmacy chain and wholesale drug distributor.
ABC MCK WBA CAH ENL ENDP
Our experts cut down 220 Zacks Rank #1 Strong Buys to the 7 most likely to jump in price immediately.
U.S. moat companies rebounded in April, with the U.S.-oriented Morningstar® Wide Moat Focus IndexSM (MWMFTR, or "U.S. Moat Index") leading the broad U.S. market as represented by the S&P 500® Index (1.47% vs. 0.38%, respectively). International moats failed to outperform the broad international markets for the first month since January 2018. Represented by the Morningstar® Global ex-US Moat Focus IndexSM (MGEUMFUN, or "International Moat Index"), international moats trailed the MSCI All Country World Index ex-USA in April (1.
G13 HSYFB PEP KIGRY MCK GIGNF CVS MORN AET GIGNY HSY
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to MCK / McKesson Corp. on message board site Silicon Investor.
as of ET